SCHEMBL5450569

SCHEMBL5450569

CCOC(=O)c1c(NC(=O)C2CC2)sc2c1CCOC2

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.69
MAPT P10636 8/20 0.61
ALDH1A1 P00352 7/20 0.61
LMNA P02545 1/20 0.61
CNR2 P34972 4/20 0.60
MAPK1 P28482 2/20 0.58
HPGD P15428 2/20 0.58
KDM4E B2RXH2 4/20 0.56
HSD17B10 Q99714 3/20 0.56
HTT P42858 1/20 0.54
TSHR P16473 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
POLB P06746 3/20 0.51
GAA P10253 2/20 0.51
HIF1A Q16665 1/20 0.51
ALOX15 P16050 1/20 0.51
ANO1 Q5XXA6 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
CNR1 P21554 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453100 0.96 CNR2 (0.67) KMT2AMAPTALDH1A1LMNACNR2
SCHEMBL5460238 0.96 CNR2 (0.64) KMT2AMAPTALDH1A1LMNACNR2
SCHEMBL5450611 0.95 CNR2 (0.66) KMT2AMAPTALDH1A1LMNACNR2
SCHEMBL4094543 0.95 CNR2 (0.66) KMT2AMAPTALDH1A1LMNACNR2
SCHEMBL4080930 0.88 CNR2 (0.69) KMT2AMAPTALDH1A1LMNACNR2
SCHEMBL5460524 0.87 ALDH1A1 (0.56) KMT2AMAPTALDH1A1LMNACNR2
SCHEMBL5460031 0.87 MAPT (0.56) KMT2AMAPTALDH1A1LMNACNR2
SCHEMBL5451004 0.85 MAPT (0.77) KMT2AMAPTALDH1A1LMNACNR2
SCHEMBL5458496 0.84 ALDH1A1 (0.56) KMT2AMAPTALDH1A1LMNACNR2
SCHEMBL5467525 0.84 ALDH1A1 (0.53) KMT2AMAPTALDH1A1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 KMT2A 4785/4885MAPT 21/4885ALDH1A1 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.